Omeros Co. (NASDAQ:OMER) Receives $22.50 Consensus Price Target from Analysts

Omeros Co. (NASDAQ:OMER) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $22.50.

OMER has been the subject of a number of research analyst reports. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw assumed coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday, December 19th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th.

Institutional Trading of Omeros

Several large investors have recently added to or reduced their stakes in OMER. Cypress Capital Group boosted its position in Omeros by 40.0% in the second quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 10,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares during the period. Rhumbline Advisers lifted its stake in Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Omeros in the 2nd quarter valued at $105,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Omeros in the third quarter worth $80,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Performance

Shares of OMER stock opened at $11.68 on Monday. The stock has a 50 day moving average price of $7.73 and a 200 day moving average price of $5.41. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60. The firm has a market capitalization of $676.86 million, a P/E ratio of -5.06 and a beta of 1.96.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.